MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the presentation of interim data at the 2008 meeting of the American Society of Hematology in San Francisco, CA, for its ongoing clinical trial of GRN163L, a telomerase inhibitor drug, in patients with relapsed and refractory multiple myeloma.
